<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02586402</url>
  </required_header>
  <id_info>
    <org_study_id>HS-EPOP2c</org_study_id>
    <nct_id>NCT02586402</nct_id>
  </id_info>
  <brief_title>Safety &amp; Efficacy of Pegolsihematide for Treatment of Anemia in Participants on Dialysis</brief_title>
  <official_title>A Phase 2, Randomized, Active-controlled, Open-label, Multi-center Study of the Safety and Efficacy of Pegolsihematide for the Correction of Anemia in Patients With CRF Undergoing Dialysis and Previously Treated With ESAs</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Jiangsu Hansoh Pharmaceutical Co., Ltd.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Jiangsu Hansoh Pharmaceutical Co., Ltd.</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate the safety and efficacy of multiple intravenous
      doses of pegol-Sihematide in participants with chronic kidney disease (CKD) who are on
      dialysis.
    </textblock>
  </brief_summary>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>October 2015</start_date>
  <completion_date type="Anticipated">August 2016</completion_date>
  <primary_completion_date type="Anticipated">August 2016</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Average reticulocytes and hemoglobin change from baseline</measure>
    <time_frame>Baseline to Week 16</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Proportion of patients whose Hb within ±1.0 g/dL of baseline during Weeks 12 to 16</measure>
    <time_frame>week 12 to 16</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Average RBC, hematokrit and reticulocytes change from baseline</measure>
    <time_frame>Baseline to Week 16</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of patients whose Hb levels were maintained within 10 to 12.0g/dL during Weeks 12 to 16</measure>
    <time_frame>week 12 to 16</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of adverse events and serious adverse events</measure>
    <time_frame>Baseline to Week 16</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">60</enrollment>
  <condition>Chronic Renal Failure</condition>
  <condition>Anemia</condition>
  <condition>Dialysis</condition>
  <arm_group>
    <arm_group_label>Pegolsihematide</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants received Pegolsihematide by intravenous injection once every 4 weeks ; the dose was adjusted throughout the study to maintain a hemoglobin target range of 11.0-12.0 grams per deciliter (g/dL).</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Epoetin Alfa</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Epoetin Alfa administration 1 to 3 times per week. The dose was adjusted throughout the study to maintain a hemoglobin target range of 11.0-12.0 g/dL.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>pegol-Sihematide</intervention_name>
    <arm_group_label>Pegolsihematide</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Epoetin Alfa</intervention_name>
    <arm_group_label>Epoetin Alfa</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Males or females≥18 and≤70, Weight ≥ 45 kilograms (kg)

          2. Participants with chronic renal failure on dialysis for ≥ 3 months prior to
             randomization.

          3. On ESAs treatment for ≥8 weeks prior to randomization with stable doses and the
             average doses ≤ 10000 IU/week

          4. Hemoglobin values of ≥ 10.0 and≤ 12.0 g/dL at Screening

          5. Patients with a transferrin saturation≥ 20% and a ferritin≥ 100 ng/mL. vitamin B12 and
             folic acid level above lower limit of normal.

          6. Signed informed consent

        Exclusion Criteria:

          1. Pregnant or lactating females

          2. Red blood cell transfusion within 3 months prior to randomization

          3. Known intolerance to any erythropoiesis stimulating agent (ESA) or pegylated molecule
             or to all parenteral iron supplementation products

          4. hemolytic syndromes or coagulation disorder

          5. hematological disease (including but not limited to myelodysplastic syndrome,
             hematological malignancy, , hemoglobinopathy, pure red cell aplasia),

          6. Chronic, uncontrolled, or symptomatic inflammatory disease (e.g., rheumatoid
             arthritis, systemic lupus erythematosus, etc.);

          7. C Reactive Protein (CRP) greater than 30 mg/L within the 4 weeks prior to
             randomization

          8. Uncontrolled or symptomatic secondary hyperparathyroidism(iPTH&gt;800pg/ml)

          9. Poorly controlled hypertension within 4 weeks prior to randomization

         10. Chronic congestive heart failure (New York Heart Association Class Ⅲ or IV)

         11. significant symptom within 6 months prior to randomization (e.g. myocardial
             infarction, serious or precarious coronary artery disease,stroke, respiratory disease,
             autoimmune disease, neuropathy, phrenopathy, hepatopathy including Active hepatitis B,
             Active hepatitis C, A positive test for HIV antibody or ALT&gt; 2 x upper limit of normal
             (ULN), AST&gt; 2 x upper limit of normal (ULN))

         12. tumor malignancy

         13. Expected survival less than 12 months

         14. A scheduled kidney transplant

         15. Major surgery (may Massive bleeding) during the study

         16. expected conception within 4 Weeks after the end of the Study Treatment

         17. The subject has participated in other clinical trial within the 12 weeks prior to
             randomization

         18. Have any other condition or prior therapy that, in the investigator's opinion, would
             make the subject unsuitable for the study, or unable or unwilling to comply with the
             study procedures
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Changli Mei</last_name>
    <role>Study Chair</role>
    <affiliation>Changzheng Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Changlin Mei</last_name>
    <phone>021-81886191</phone>
    <email>Chlmei1954@126.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Changzheng Hospital</name>
      <address>
        <city>Shanghai</city>
        <state>Shanghai</state>
        <zip>200003</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Changlin Mei</last_name>
      <phone>021-81886191</phone>
      <email>Chlmei1954@126.com</email>
    </contact>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>October 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>October 23, 2015</study_first_submitted>
  <study_first_submitted_qc>October 23, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 26, 2015</study_first_posted>
  <last_update_submitted>October 23, 2015</last_update_submitted>
  <last_update_submitted_qc>October 23, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">October 26, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>ESAs CKD</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Anemia</mesh_term>
    <mesh_term>Renal Insufficiency</mesh_term>
    <mesh_term>Kidney Failure, Chronic</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Epoetin Alfa</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

